With
the increasing strategic alliances between needle-free drug delivery
devices manufacturers, the business landscape of this market
demonstrates a rather consolidated structure. In 2014, the top three
companies, namely, Zogenix, 3M, and Antares Pharma Inc., jointly held
a share of more than 60% in the overall market, finds Transparency
Market Research (TMR) in a new study.
Get
Needle Free Drug Delivery Devices Industrial Analysis:
Apart
from mergers, acquisitions, and partnerships, leading companies are
currently focusing on introducing advanced devices based on novel
technologies to strengthen their presence in this market. Looking
forward, the vast array of technically advanced devices - in the
pipeline at present - will further intensify the competition in the
worldwide market for needle-free drug delivery devices in the near
future.
Growing
Preference for Painless Delivery of Medicines Fuels Demand for
Needle-Free Drug Delivery Devices
The
growing preference for efficient and painless delivery of medicines
is leading the drug delivery market towards needle-free injection
systems. As these systems make use of a liquid drug delivery
technology that works effectively with already available drug
formulations, the development costs on these products are very low.
This has encouraged a number of medical devices manufacturers to
invest in needle-free drug delivery devices, boosting the market’s
growth.
In
addition to this, the increasing need to prevent needle-stick
injuries is likely to stimulate the adoption of needle-free drug
delivery devices significantly during the forecast period. The rising
prevalence of infectious diseases such as dengue, hepatitis, and
AIDS, and various cardiovascular and neurological diseases, which
require continual administration of drugs, is also projected to
create substantial demand for these devices over the next few years.
Despite
North America’s Dominance, Asia Pacific to Report Fastest Growth
According
to TMR’s estimates, the opportunity in the global market for
needle-free drug delivery devices that valued at US$5.4 bn in 2014,
is likely to increase at a CAGR of 9.90% during the period from 2015
to 2023 and possibly worth US$13 bn by the end of the forecast
period.
Needle
Free Drug Delivery Devices Market Description:
In
2014, North America led the global market with a share of more than
40% and was closely followed by Europe. During the forecast period,
North America will remain the dominant regional market; however, it
will lose a significant amount of its market shares to Asia Pacific.
The latter, on the other hand, will emerge as the fastest growing
market for needle-free drug delivery devices in the coming years.
Needle-free
drug delivery devices are mostly utilized for the administration of
insulin in the human body. The insulin delivery segment has been
leading the application segment since the last few years and is
projected to remain dominant over the coming years.
Competing
needle-fee technologies, such as inhaler, transdermal, and various
other novel needle-free technologies witnessed the highest demand in
2014. However, jet injectors are likely to exhibit the fastest growth
rate over the forecast period.
No comments:
Post a Comment